GAE Using Embosphere Microspheres vs Corticosteroid Injections for Treatment of Symptomatic Knee OA (MOTION)

NCT05818150 · tracked via the Priya Life Science UK tracker

Sponsor

Merit Medical Systems, Inc.

Phase

Not applicable

Started

2024-01-16

Last updated

2025-10-24

Condition(s) studied

Knee Osteoarthritis

Investigational drug(s) / intervention(s)

Embosphere MicrospheresCorticosteroid injection

Embosphere Microspheres: Embolic Agent: Embosphere Microspheres

Corticosteroid injection: Corticosteroid injection

Study summary

This multicenter, prospective, interventional trial is designed to assess the outcome of subjects with symptomatic knee osteoarthritis (OA) that are randomized to treatment with either genicular artery embolization (GAE) using Embosphere Microspheres or steroid injection over a period of 24 months.

Eligibility

Sex

ALL

Min age

21 Years

Max age

—

Healthy volunteers

Key Inclusion Criteria: Provides written informed consent Age ≥21 years Mild to severe knee pain, defined as a WOMAC Pain score of ≥8 out of 20 (in the target knee) Pain refractory to conservative therapies for at least 90 days prior to enrollment/randomization. Kellgren-Lawrence grade 1, 2, 3 or 4 Key Exclusion Criteria: Planned major surgical or endovascular procedures ≤ 30 days after the index procedure. Advanced atherosclerosis Known history of rheumatoid or infectious arthritis. Prior knee replacement surgery of the target knee.

Primary outcome measure(s)

Primary Efficacy Endpoint — 6 months
Clinical Success defined as ≥50% improvement in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale from baseline to 6 months without the need for additional intervention.
Primary Safety Endpoint — 6 months
Freedom from treatment-related safety events through 6 months (180 days) following the index procedure.

Trial sites (27)

Facility	City	Region
Memorial Care Long Beach Medical Center	Long Beach	California
Georgetown University Medical Center	Washington D.C.	District of Columbia
MedStar Washington Hospital Center	Washington D.C.	District of Columbia
Emory University School of Medicine	Atlanta	Georgia
Biotech Clinical Research/ Georgia Vascular Institute	College Park	Georgia
Northwestern University	Chicago	Illinois
Massachusetts General Hospital	Boston	Massachusetts
Saint Louis University	St Louis	Missouri
Atlantic Medical Imaging	Galloway	New Jersey
Rutgers Health	Newark	New Jersey
Northwell Health	Manhasset	New York
Weill Cornell Medicine	New York	New York
Atlas Interventional	Williamsville	New York
Prostate Centers USA	Raleigh	North Carolina
Sunrise Vascular Center	Sanford	North Carolina
The Ohio State University	Columbus	Ohio
Cardiovascular Health Clinic	Oklahoma City	Oklahoma
Prostate Centers USA	Falls Church	Virginia
Prostate Centers USA	Leesburg	Virginia
Liverpool Hospital	Liverpool	Australia
Hospital de Clínicas de Passo Fundo	Passo Fundo	Brazil
University of Sao Paulo	São Paulo	Brazil
Vancouver General Hospital	Vancouver	British Columbia
CHUM - Centre hospitalier de l'Université de Montréal	Montreal	Canada
North Shore Hospital/ Te Whatu Ora - Waitemata	Takapuna	New Zealand
University Hospitals Dorset	Bournemouth	United Kingdom
Grange University Hospital	Cwmbran	United Kingdom

More Merit Medical Systems, Inc. trials in the UK

Bearing nsPVA Embolization for Uterine Artery Embolization (BETTER-UAE) Recruiting

Merit WRAPSODY™ Endoprosthesis for Treatment of Stenosis or Occlusion (WRAP) Active, not recruiting

Other trials for the same condition

Observational Clinical Investigation of Arthrosamid in Knee Osteoarthritis Active, not recruiting

Genicular Artery Embolisation for Knee Osteoarthritis II Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05818150 on ClinicalTrials.gov ↗ ← All trials in the UK